N’-phenyl-4,6-bis(arylamino)-1,3,5-triazine-2-carbohydrazides derivatives 27–29 (Figure 8) were evaluated for their ability to inhibit Rad6B ubiquitin conjugation in the human cancer cell lines: OV90 (ovarian cancer), H1299 (human non-small cell lung carcinoma), A549, MCF-7, MDA-MB231, and HT-29 (colon cancer). Here, UBE2B is linked to cancer.